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Hürthle cell predominant thyroid nodules often confound the diagnostic utility of fine needle aspiration biopsy (FNAB) with
cytology often interpreted as a Hürthle cell lesion with an indeterminate risk of malignancy, Bethesda category (BC) III or IV.
Molecular diagnostics for Hürthle cell predominant nodules has also been disappointing in further defining the risk of malignancy.
We present a case of a slowly enlarging nodule within a goiter initially reported as benign on FNAB, BC II but on subsequent FNAB
suspicious for a Hürthle cell neoplasm, BC IV. The patient had initially requested a diagnostic lobectomy for a definitive diagnosis
despite a higher risk of malignancy based on the size of the nodule > 4 cm alone. To better tailor this patient’s treatment plan, a newer
expanded gene mutation panel, ThyroSeq v3 that includes copy number alterations (CNAs) and was recently found to have greater
positive predictive value (PPV) for identifying Hürthle cell carcinoma (HCC), was performed on the FNAB material. Molecular
profiling with ThyroSeq v3 was able to predict a greater risk of carcinoma, making a more convincing argument in favor of total
thyroidectomy. Surgical pathology confirmed a Hürthle cell carcinoma with 5 foci of angioinvasion and foci of capsular invasion.

1. Introduction
Thyroid nodules with a predominance of Hürthle cells often
confound the diagnostic utility of fine needle aspiration
biopsy with cytology often interpreted as a Hürthle cell lesion
with an indeterminate risk of malignancy, Bethesda category
III or IV. Molecular diagnostics for Hürthle cell predominant
thyroid nodules, with the exception of medullary thyroid
carcinoma, has also been disappointing in further defining
the risk of malignancy. This diagnostic challenge occurs
because Hürthle cells or oncocytic metaplasia is associated
with benign nodules (cell-mediated autoimmune thyroiditis,
humoral-mediated Graves’ disease, and hyperplastic nodules
in multinodular goiters (MNG)). Hürthle cells also occur in
neoplastic conditions such as Hürthle cell adenoma, Hürthle
cell carcinoma, and the oncocytic variant of papillary thyroid

carcinoma. Medullary carcinoma, a C-cell derived neoplasm,
can also exhibit an oncocytic appearance and is included in
the differential diagnosis of Hürthle cell lesions.
Furthermore, different areas within the same nodule may
yield very different degrees of Hürthle cell differentiation
further confusing the cytologic interpretation. There are
additional challenges; a benign Hürthle cell adenoma cannot
be distinguished from a HCC without demonstrating either
capsular or vascular invasion found after surgical removal
on careful histopathologic assessment at multiple levels. The
biological behavior of HCC varies and can present either as a
minimally invasive or as a widely invasive tumor. Hürthle cell
carcinoma may have a more aggressive biological behavior
compared with the other well-differentiated thyroid cancers
and is associated with a higher rate of distant metastases.
Hürthle cell carcinoma often has less radioiodine avidity
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compared with other well-differentiated thyroid cancers,
mandating a more complete thyroidectomy, especially for
optimal adjuvant therapy for a subset of tumors with some
RAI avidity in the setting of locally aggressive HCC, regional
lymph node involvement, or distant metastases [1].
We present a case of a slowly enlarging nodule within a
MNG initially reported as benign on FNA cytology BC II
but on subsequent FNA cytology interpreted as a Hürthle
cell neoplasm or suspicious for a Hürthle cell neoplasm, BC
IV. Molecular profiling using ThyroSeq v2 next-generation
gene sequencing [2] revealed an absence of gene mutations or
fusions but strong overexpression of the MET gene. Since this
finding alone could not reliably predict a HCC, the patient
had initially requested a diagnostic lobectomy for a definitive
pathologic diagnosis despite a higher risk of malignancy
based on the size of the nodule > 4 cm alone. To better
tailor this patient’s treatment plan, the ThyroSeq v3 panel,
recently found to have greater positive predictive value (PPV)
for identifying Hürthle cell malignancies, was performed
on the FNA material. Molecular profiling with ThyroSeq
v3 was able to predict a greater risk of HCC, making a
more convincing argument in favor of total thyroidectomy.
This case report illustrates the important role of molecular
diagnostics, specifically, ThyroSeq v3 in tailoring the often
difficult clinical management of Hürthle cell thyroid nodules
for optimal surgical treatment.

2. Case Presentation
This patient was a generally healthy 62-year-old male with
a left lobe complex nodule within a nontoxic multinodular
goiter that had been enlarging for approximately 3 years. In
2015, the patient had a FNAB reported as benign, BC II.
Because of continued growth, he had a second FNA biopsy
approximately six months later reported as a Hürthle cell
neoplasm or suspicious for a Hürthle cell neoplasm, BC IV
with Oncocytic / Hürthle cells dispersed mostly singly and in
small fragments in a background of lysed blood. CKAE1/AE3,
TTF-1, and thyroglobulin immunostains were positive (Figure 1(a)). Molecular testing with ThyroSeq v2 revealed an
absence of gene mutations or fusions but overexpression of
the MET gene with an uncertain increased risk of malignancy.
After repeat ultrasound imaging, the nodule had grown from
4.9 to 6.0 cm over the course of 1 year. He was euthyroid
with negative anti-thyroid antibodies. There was no family
history of thyroid cancer or known radiation exposures in
his youth. He had no obstructive symptoms despite the size
of the mass and denied shortness of breath, dysphagia, neck
pain, neck pressure, or recent voice changes. His weight
had been stable and appetite good. His past medical history
was significant for a retinal detachment, hypertension, and
inguinal hernia with a surgical history limited to eye surgery
and hernia repair. He denied tobacco or alcohol use. On
exam, the patient had an enlarged, firm thyroid gland with
the left thyroid lobe causing significant tracheal deviation to
the right. A neck CT scan demonstrated a markedly enlarged
left thyroid lobe (7.2 cm in sagittal height) causing significant
rightward tracheal deviation, minimal tracheal compression,
and slight early substernal extension (Figure 2). He had
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multiple opinions from both endocrinologists and surgeons
with various recommendations from left thyroid lobectomy
to total thyroidectomy. The patient had initially contemplated
a hemithyroidectomy due to concerns for voice impairment
that could impact his occupation as an attorney.
After a second surgical consultation, he elected to have
another, more advanced molecular test performed on the
same FNAB specimen. The ThyroSeq v3 test has been
designed to improve the performance of its previous version, ThyroSeq v2, specifically with respect to Hürthle cell
tumors. This has been achieved by expanding the number of
gene markers analyzed for mutations and gene fusions and
particularly by incorporating the analysis of copy number
alterations (CNAs), which are common in Hürthle cell
cancers. ThyroSeq v3 test results in this case showed CNAs
involving multiple chromosomes with the pattern of genome
haploidization which predicted a much greater probability
that the left lobe nodule represented a Hürthle cell malignancy rather than Hürthle cell metaplasia or an adenoma.
Based on the additional information provided by ThyroSeq
v3, in July, 2017, the patient elected a total thyroidectomy.
At surgery, the overlying strap muscles were superficially
adherent to the thyroid capsule on the left with a suspicion
of minimal extrathyroidal extension of the tumor and a
layer of muscle was left attached to the specimen. There
were no paratracheal lymph nodes. He did require single
gland parathyroid autotransplantation. Postoperatively, his
parathyroid hormone and calcium levels were within normal
limits. On final surgical pathology, an encapsulated 7 cm
Hürthle cell carcinoma with 5 foci of angioinvasion was
found along with foci of capsular invasion, without extrathyroidal extension (Figure 1(b)). A second opinion was sought
and the reviewing pathologist reported 4 foci of capsular
invasion and 3 foci of vascular invasion. The number of
foci of vascular invasion was prognostically important and
prompted more aggressive treatment and follow-up.
One month postoperatively, thyroglobulin was 308
ng/mL. A small thyroid remnant with 2.4% uptake in the
surgical bed was found on I-131 whole body scan. An FDGPET scan was negative for any activity in the thyroidectomy
bed or for distant metastatic disease; therefore he was given 30
mCi of radioactive iodine to ablate the remnant. At this time,
his thyroglobulin had decreased from 308 to 8.71 ng/mL. His
postablation, I-131 whole body scan showed ablation of the
thyroid remnant and no evidence of metastatic disease. By
10/27/2017, the thyroglobulin had decreased further to 0.2
ng/mL with no detectable thyroglobulin antibodies and a
TSH of 0.09 uIU/ml indicating a favorable early response to
initial treatment.

3. Discussion
In the past, cytologic assessment, with or without molecular
profiling, of Hürthle cell nodules failed to accurately predict
the risk of HCC. The presence of Hürthle or oncocytic cells
in cytologic specimens from FNA samples is often seen in
a wide range of thyroid pathologies, the majority of which
are benign. The finding of predominance of Hürthle cells is
usually interpreted as suspicious for a follicular neoplasm,
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(a) FNA diagnosis: Hürthle cell neoplasm or suspicious for a Hürthle
cell neoplasm, Bethesda Category IV. The aspirate shows predominantly
single cells, many with degenerated friable cytoplasm, imparting a
pseudo-necrotic background (A). The cells have abundant granular
eosinophilic cytoplasm with eccentric and slightly enlarged nuclei, giving
a plasmacytoid appearance (ThinPrep, Papanicolaou x 40). The neoplastic cells stain with pankeratin AE1/AE3 (B), TTF-1 (C), and thyroglobulin
(D), confirming their thyroid follicular origin and excluding medullary
carcinoma or histiocytes

(b) Invasive, follicular carcinoma, oncocytic (Hürthle cell) variant. The
tumor shows a trabecular/solid architecture (A), composed of large,
polygonal cells with abundant granular eosinophilic cytoplasm. The
cells have round to slightly irregular nuclei with prominent centrally
placed nucleoli (B). Foci of capsular (A) and vascular invasion are
identified (C, D)

Figure 1

(a)

(b)

Figure 2: Preoperative neck CT without contrast, demonstrating a large left thyroid lobe mass with displacement of the trachea, mild
compression, and early substernal extension; representative axial (a) and coronal views (b).

Hürthle cell type, BC IV, conferring a positive predictive
value (PPV) for malignancy of approximately 15-30%. The
high frequency of nonneoplastic Hürthle cell proliferation
in patients with Hashimoto’s thyroiditis can be a diagnostic
dilemma for the cytopathologist [3]. With the advent of
molecular profiling, the hope was to minimize the need
for diagnostic thyroid lobectomy for benign nodules, for
tumor prognostication to tailor the extent of thyroid surgery
for optimal cure and to prevent tumor recurrence. The
Afirma Gene Expression Classifier developed by Veracyte,
Inc. (South San Francisco, CA) has been shown to have a
high negative predictive value (NPV) for most benign thyroid
nodules but with a poor PPV for malignancy and renders
a large number of FNA samples with various proportions
of nonneoplastic Hürthle cells as suspicious for malignancy,
thus triaging most of these patients to thyroid surgery [4].

ThyroSeq is a multigene next-generation sequencingbased test for thyroid nodules. The early version, ThyroSeq
v2, utilized the analysis of 56 genes predominantly for
point mutations and gene fusions, as well as for limited
gene expression alterations [2]. The expanded version of
the test, ThyroSeq v3, interrogated 112 genes and is based
not only on the analysis of point mutations, gene fusions,
and gene expression alterations, but also on copy number
alterations (CNAs) [5]. The latter is particularly important
for predicting Hürthle cell carcinomas, which are known to
have a characteristic pattern of CNAs with almost complete
genome haploidization [6]. Taking advantage of the analysis
of CNAs, in the validation study, ThyroSeq v3 showed reliable
performance in Hürthle cell cancers, offering 93% sensitivity
and 69% specificity [5]. In a preliminary report from a recent
multicenter study which included 10 Hürthle cell carcinomas,
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34 Hürthle cell adenomas, and 5 hyperplastic nodules with
Hürthle cell predominance, the performance of ThyroSeq
v3 allowed for the detection of all HCCs (sensitivity, 100%;
95%CI: 69.2- 100%), with all 5 hyperplastic nodules with
Hürthle cell predominance classified as negative and overall
test specificity of 66.7% (95%CI: 49.8-80.9%) [7].
In an era of patient-guided decision-making and the
ability to tailor the extent of surgery based on preoperative FNA biopsy prognostication, molecular profiling of
thyroid nodules has become increasingly utilized. Despite
the limitations of molecular testing and the variance in both
PPV and NPV with a varying prevalence of malignancy in
different populations, its utility in selecting patients for active
surveillance, thyroid lobectomy, and total thyroidectomy will
likely increase, especially as their overall accuracy improves
over time. The particular advantages of ThyroSeq v3 over
ThyroSeq v2 in guiding the extent of thyroid surgery for
indeterminate Hürthle cell cytopathology are illustrated by
this case report and helped tailor the best treatment for this
patient with a Hürthle cell carcinoma who would otherwise
have likely needed a completion thyroidectomy.
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